ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17: 162–173.
2.
ReichDSLucchinettiCFCalabresiPA.Multiple sclerosis. N Engl J Med2018; 378: 169–180.
3.
RojasJIPatruccoLCristianoE. An asymptomatic new lesion on MRI is a relapse and should be treated accordingly – Yes. Mult Scler2019; 25: 1842–1843.
4.
ChardDTTripA. An asymptomatic new lesion on MRI is a relapse and should be treated accordingly – No. Mult Scler2019; 25: 1843–1845.
5.
TintoreMRoviraARioJ, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015; 138(Pt 7): 1863–1874.
6.
BrownleeWJAltmannDRPradosF, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain2019; 142(8): 2276–2287.
7.
KriegerSCCookKDe NinoS, et al. The topographical model of multiple sclerosis: A dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm2016; 3(5): e279.
8.
Di GregorioMGaetaniLEusebiP, et al. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. J Neurol2018; 265(3): 522–529.
9.
BrusaferriFCandeliseL.Steroids for multiple sclerosis and optic neuritis: A meta-analysis of randomized controlled clinical trials. J Neurol2000; 247(6): 435–442.
10.
SormaniMPBruzziP.MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. Lancet Neurol2013; 12(7): 669–676.
11.
GasperiniCProsperiniLTintoreM, et al. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. Neurology2019; 92(4): 180–192.
12.
GeurtsJJPouwelsPJUitdehaagBM, et al. Intracortical lesions in multiple sclerosis: Improved detection with 3D double inversion-recovery MR imaging. Radiology2005; 236(1): 254–260.
